Optimize your assays using recombinant antibodies selected for desired affinity
Presented at PEGS Europe, Lisbon 3-7 November 2014 and at Antibody Engineering and Therapeutics, Huntington Beach 7-11 December 2014
This poster illustrates the suitability of HuCAL® recombinant custom monoclonal antibodies for Pharmacokinetic (PK) assays and Immune Reponse (IR) assays and includes
Read more about using HuCAL technology to generate antibodies to biosimilars and novel biotherapeutics
HuCAL® is a registered trademark of MorphoSys AG.